The journal of prevention of Alzheimer's disease
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease..
12:-.
2025
-
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults..
12:-.
2025
-
Eligibility for donanemab trial in a population-based study of cognitive aging..
12:-.
2025
-
Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials..
12:-.
2025
-
Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study..
11:1406-1409.
2024
-
Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality..
11:97-107.
2024
-
Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study..
11:814-822.
2024
-
Cognitive Performance and Incident Alzheimer's Dementia in Men Versus Women..
11:162-170.
2024
-
Estimating Socio-Economic Status for Alzheimer's Disease Trials..
11:1418-1425.
2024
-
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults..
11:339-347.
2024
-
Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease..
11:1696-1702.
2024
-
Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease..
11:869-873.
2024
-
Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure..
11:1572-1580.
2024
-
Investigating the Factor Structure of the Preclinical Alzheimer Cognitive Composite and Cognitive Function Index across Racial/Ethnic, Sex, and Aβ Status Groups in the A4 Study..
11:48-55.
2024
-
Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease..
11:823-830.
2024
-
Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial..
11:874-880.
2024
-
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4..
11:831-837.
2024
-
The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants..
11:1-6.
2024
-
Who Benefited Most from the Internet-Based Conversational Engagement RCT (I-CONECT)? Application of the Personalized Medicine Approach to a Behavioral Intervention Study..
11:639-648.
2024
-
Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease..
10:112-119.
2023
-
Editorial: Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness..
10:5-6.
2023
-
Genotypic Effects of the TOMM40'523 Variant and APOE on Longitudinal Cognitive Change over 4 Years: The TOMMORROW Study..
10:886-894.
2023
-
Geroscience and Alzheimer's Disease Drug Development..
10:620-632.
2023
-
Lecanemab: Appropriate Use Recommendations..
10:362-377.
2023
-
Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer's Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Models and a Probability Calculator..
10:301-313.
2023
-
Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics..
10:633-646.
2023
-
US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging..
10:34-40.
2023
-
Validity of Normative Volumetric Estimates from Open Access Software in Amnestic Mild Cognitive Impairment..
10:236-243.
2023
-
Aducanumab: Appropriate Use Recommendations Update..
9:221-230.
2022
-
Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid..
9:617-624.
2022
-
Anxiety and Depressive Symptoms and Cortical Amyloid-β Burden in Cognitively Unimpaired Older Adults..
9:286-296.
2022
-
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force..
9:569-579.
2022
-
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease..
9:507-522.
2022
-
Diversifying Recruitment Registries: Considering Neighborhood Health Metrics..
9:119-125.
2022
-
Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults..
9:297-305.
2022
-
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults..
9:801-808.
2022
-
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials..
9:241-246.
2022
-
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial..
9:22-29.
2022
-
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial..
9:255-261.
2022
-
A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment..
8:135-141.
2021
-
Aducanumab: Appropriate Use Recommendations..
8:398-410.
2021
-
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review..
8:520-533.
2021
-
Current State of Self-Administered Brief Computerized Cognitive Assessments for Detection of Cognitive Disorders in Older Adults: A Systematic Review..
8:267-276.
2021
-
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging..
8:414-424.
2021
-
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data..
8:257-262.
2021
-
Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study..
8:199-209.
2021
-
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force..
8:306-312.
2021
-
The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial..
8:59-67.
2021
-
The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program..
8:286-291.
2021
-
Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research..
7:206-207.
2020
-
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials..
7:213-218.
2020
-
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD)..
7:219-225.
2020
-
Self-Administered Cognitive Testing by Older Adults At-Risk for Cognitive Decline..
7:283-287.
2020
-
TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology..
7:226-233.
2020
-
The Future of Anti-Amyloid Trials..
7:146-151.
2020
-
The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years..
7:234-241.
2020
-
The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview..
7:208-212.
2020
-
Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred..
6:112-120.
2019
-
What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force..
5:171-174.
2018
-
Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly..
4:81-86.
2017
-
Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries..
4:3-11.
2017
-
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials..
4:116-124.
2017
-
Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies..
4:236-241.
2017
-
Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network..
3:114-120.
2016
-
The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials..
3:8-12.
2016
-
A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS)..
2:227-241.
2015
-
The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease..
2:242-253.
2015
-
Establishing Clinical Relevance in Preclinical Alzheimer's Disease..
2:85-87.
2015
-
Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer's Disease: Transforming Functional Scores into Levels of Dependence..
2:115-120.
2015
-
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations..
1:181-202.
2014
-
Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making..
1:117-123.
2014
Identity
International Standard Serial Number (ISSN)